Heterozygous familial hypercholesterolemia: prevalence and control rates

References

• Lewington S, Whitlock G, Clarke R, et al.; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839.
   PubMed Web of Science ®Google Scholar
• Pérez De Isla L, Alonso R, Mata N, et al. SAFEHEART Investigators. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish Familial Hypercholesterolaemia cohort study). Arterioscler Thromb Vasc Biol. 2016;36(9):2004–2010.
   PubMed Web of Science ®Google Scholar
• Humphries SE, Cooper JA, Seed M, et al. Simon Broome Familial Hyperlipidaemia register group. Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register. Atherosclerosis. 2018;274:41–46.
   PubMed Web of Science ®Google Scholar
• Perez-Calahorra S, Laclaustra M, Marco-Benedí V, et al. Dyslipemia Registry of Spanish Arteriosclerosis society. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis. 2019;284:245–252.
   PubMed Web of Science ®Google Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
   PubMed Web of Science ®Google Scholar
• Besseling J, Hovingh GK, Huijgen R, et al. Statins in Familial Hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016;68(3):252–260.
   PubMed Web of Science ®Google Scholar
• Polychronopoulos G, Tziomalos K. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2017;10(12):1375–1381.
   PubMed Web of Science ®Google Scholar
• Pećin I, Hartgers ML, Hovingh GK, et al. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol. 2017;24(13):1383–1401.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Humphries SE, et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490.
   PubMed Web of Science ®Google Scholar
• Zamora A, Masana L, Comas-Cufí M, et al. XULA and ISV-Girona groups. Familial hypercholesterolemia in a European Mediterranean population-Prevalence and clinical data from 2.5 million primary care patients. J Clin Lipidol. 2017;11(4):1013–1022.
   PubMed Web of Science ®Google Scholar
• Guglielmi V, Bellia A, Pecchioli S, et al. What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database. Int J Cardiol. 2016;223:701–705.
   PubMed Web of Science ®Google Scholar
• Green P, Neely D, Humphries SE. Medway FH Audit Steering Committee. Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics. J Eval Clin Pract. 2016;22(3):341–348.
   PubMed Web of Science ®Google Scholar
• Perak AM, Ning H, De Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the Familial Hypercholesterolemia Phenotype. Circulation. 2016;134(1):9–19.
   PubMed Web of Science ®Google Scholar
• Jung KJ, Koh H, Choi Y, et al. Familial hypercholesterolemia and atherosclerotic cardiovascular mortality among Korean adults with low levels of serum cholesterol. Atherosclerosis. 2018;278:103–109.
   PubMed Web of Science ®Google Scholar
• Zafrir B, Jubran A, Lavie G, et al. Clinical determinants and treatment gaps in familial hypercholesterolemia: data from a multi-ethnic regional health service. Eur J Prev Cardiol. 2017;24(8):867–875.
   PubMed Web of Science ®Google Scholar
• Harada PH, Miname MH, Benseñor IM, et al. Familial hypercholesterolemia prevalence in an admixed racial society: sex and race matter. The ELSA-Brasil. Atherosclerosis. 2018;277:273–277.
   PubMed Web of Science ®Google Scholar
• Vickery AW, Ryan J, Pang J, et al. Increasing the detection of Familial Hypercholesterolaemia using general practice electronic databases. Heart Lung Circ. 2017;26(5):450–454.
   PubMed Web of Science ®Google Scholar
• Hu P, Dharmayat KI, Stevens CAT, et al., Prevalence of Familial Hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 141(22): 1742–1759. 2020.
   PubMed Web of Science ®Google Scholar
• Santos RD, Gidding SS, Hegele RA, et al. International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016;4:850–861.
   PubMed Web of Science ®Google Scholar
• Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with Familial Hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134(10):698–709.
   PubMed Web of Science ®Google Scholar
• Gulizia MM, Maggioni AP, Abrignani MG, et al. POSTER investigators. Prevalence of familial hypercholeSTerolaemia (FH) in Italian patients with coronary artery disease: the POSTER study. Atherosclerosis. 2020;308:32–38.
   PubMed Web of Science ®Google Scholar
• Rerup SA, Bang LE, Mogensen UM, et al. The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. Am Heart J. 2016;181:35–42.
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Kosmas N, Tsirebolos G, et al. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden. J Clin Lipidol. 2019;13(3):502–508.
   PubMed Web of Science ®Google Scholar
• De Backer G, Besseling J, Chapman J, et al. EUROASPIRE investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis. 2015;241(1):169–175.
   PubMed Web of Science ®Google Scholar
• Shi HW, Yang JG, Wang Y, et al. The Prevalence of Familial Hypercholesterolemia (FH) in Chinese patients with Acute Myocardial Infarction (AMI): data from Chinese Acute Myocardial Infarction (CAMI) Registry. Front Cardiovasc Med. 2020;7:113.
   PubMed Web of Science ®Google Scholar
• Li JJ, Li S, Zhu CG, et al. Familial Hypercholesterolemia Phenotype in Chinese patients undergoing Coronary Angiography. Arterioscler Thromb Vasc Biol. 2017;37(3):570–579.
   PubMed Web of Science ®Google Scholar
• Ohmura H, Fukushima Y, Mizuno A, et al. Research Committee on Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan. Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in patients with Acute Coronary Syndrome. Int Heart J. 2017;58(1):88–94.
   PubMed Web of Science ®Google Scholar
• Sawhney JPS, Prasad SR, Sharma M, et al. Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India. Indian Heart J. 2019;71(2):118–122.
   PubMedGoogle Scholar
• Kramer AI, Trinder M, Brunham LR. Estimating the Prevalence of Familial Hypercholesterolemia in Acute Coronary Syndrome: a systematic review and meta-analysis. Can J Cardiol. 2019;35(10):1322–1331.
   PubMed Web of Science ®Google Scholar
• Perez De Isla L, Alonso R, Watts GF, et al. SAFEHEART Investigators. Attainment of LDL-cholesterol treatment goals in patients with Familial Hypercholesterolemia: 5-year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67(11):1278–1285.
   PubMed Web of Science ®Google Scholar
• Vrablik M, Raslová K, Vohnout B, et al. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: results of the PLANET registry. Atherosclerosis. 2018;277:355–361.
   PubMed Web of Science ®Google Scholar
• Rizos CV, Elisaf MS, Skoumas I, et al. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH. Atherosclerosis. 2018;277:308–313.
   PubMed Web of Science ®Google Scholar
• Schmidt N, Dressel A, Grammer TB, et al. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: the CaReHigh Registry. Atherosclerosis. 2018;277:314–322.
   PubMed Web of Science ®Google Scholar
• D’Erasmo L, Commodari D, Di Costanzo A, et al. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study. Nutr Metab Cardiovasc Dis. 2027–35;30:2020.
   Google Scholar
• deGoma EM, Ahmad ZS, O’Brien EC, et al. Treatment gaps in adults with Heterozygous Familial Hypercholesterolemia in the United States: data from the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016;9(3):240–249.
   PubMedGoogle Scholar
• Mehta R, Martagon AJ, Galan Ramirez GA, et al. Mexican Familial Hypercholesterolemia Group. Familial hypercholesterolemia in Mexico: initial insights from the national registry. J Clin Lipidol. 2021;15(1):124–133.
   PubMed Web of Science ®Google Scholar
• Kayikcioglu M, Tokgozoglu L, Dogan V, et al. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? Atherosclerosis. 2018;277:341–346.
   PubMed Web of Science ®Google Scholar
• Van Delden XM, Huijgen R, Wolmarans KH, et al. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: minority at target despite large reductions in LDL-C. Atherosclerosis. 2018;277:327–333.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Almahmeed W, Al-Rasadi K, et al., ICLPS study group. Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: the International ChoLesterol management practice study. J Clin Lipidol. 13(4): 594–600. 2019.
   PubMed Web of Science ®Google Scholar
• EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, De Marco M, Stevens CAT, et al. EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) investigators. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234–255.
   PubMed Web of Science ®Google Scholar
• Pećin I, Reiner Ž. Novel experimental agents for the treatment of Hypercholesterolemia. J Exp Pharmacol. 2021;13:91–100.
   PubMedGoogle Scholar
• Reiner Z. Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ Res. 2014;114(2):233–235.
   PubMed Web of Science ®Google Scholar
• Ž R, Sahebkar A. Treatment of children with heterozygous familial hypercholesterolemia. Int J Cardiol. 2020;304:177–178.
   PubMed Web of Science ®Google Scholar
• De Ferranti SD, Shrader P, Linton MF, et al. Children with Heterozygous Familial Hypercholesterolemia in the United States: data from the Cascade Screening for Awareness and Detection-FH Registry. J Pediatr. 2021;229:70–77.
   PubMed Web of Science ®Google Scholar
• Benekos T, Kosmeri C, Vlahos A, et al. Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece. J Pediatr Endocrinol Metab. 2020;33(4):533–538.
   PubMed Web of Science ®Google Scholar
• Bogsrud MP, Langslet G, Wium C, et al. Treatment goal attainment in children with familial hypercholesterolemia: a cohort study of 302 children in Norway. J Clin Lipidol. 2018;12(2):375–382.
   PubMed Web of Science ®Google Scholar
• Banach M, Penson PE, Fras Z, et al. FH Europe and the International Lipid Expert Panel (ILEP). Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol Res. 2020;158:104891.
   PubMed Web of Science ®Google Scholar